Bayer Files Additional Application For Fosrenol For CKD Hyperphosphatemia Improvement
This article was originally published in PharmAsia News
Executive Summary
Bayer Pharmaceuticals announced Oct. 3 it filed an additional application for Fosrenol chewable tablets / granule sachets (lanthanum carbonate hydrate), used to absorb and remove excess phosphorus from the body, for “improvement of hyperphosphatemia in patients with chronic kidney disease in the retention period.”